Article
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Cancer - 1 Feb 2015
Villaruz Liza C, Socinski Mark A, Abberbock Shira, Berry Lynne D, Johnson Bruce E, Kwiatkowski David J, Iafrate A John, Varella-Garcia Marileila, Franklin Wilbur A, Camidge D Ross, Sequist Lecia V, Haura Eric B, Ladanyi Mark, Kurland Brenda F, Kugler Kelly, Minna John D, Bunn Paul A, Kris Mark G
Abstract excerpt
BACKGROUND: The advent of effective targeted therapy for BRAF(V600E) -mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.